(Press-News.org) A novel software tool, developed at The Children's Hospital of Philadelphia, streamlines the detection of disease-causing genetic changes through more sensitive detection methods and by automatically correcting for variations that reduce the accuracy of results in conventional software. The software, called ParseCNV, is freely available to the scientific-academic community, and significantly advances the identification of gene variants associated with genetic diseases.
"The algorithm we developed detects copy number variation associations with a higher level of accuracy than that available in existing software," said the lead inventor of ParseCNV, Joseph T. Glessner, of the Center for Applied Genomics at The Children's Hospital of Philadelphia. "By automatically correcting for variations in the length of deleted or duplicated DNA sequences from one individual to another, ParseCNV produces high-quality, highly replicable results for researchers studying genetic contributions to disease."
Glessner is the lead author of a study describing ParseCNV, published Jan. 4 in Nucleic Acids Research.
Copy number variations (CNVs) are particular sequences of DNA, ranging in length from 1000 to millions of nucleotide bases, which may be deleted or duplicated. While in any given region of a person's DNA, CNVs are very rare, everyone's genome has CNVs, many of which play important roles in causing or influencing disease.
In searching for associations between CNVs and diseases, researchers typically perform case-control studies, comparing DNA samples from patients to DNA from healthy individuals, looking for telltale differences in how CNVs are overrepresented or underrepresented.
CNVs, however, occur in multiple types among individuals, said senior author Hakon Hakonarson, M.D., Ph.D., director of the Center for Applied Genomics at The Children's Hospital of Philadelphia. "One person may have a 60-kilobase deletion, while another may have a 100-kilobase deletion; that may determine the difference between a healthy state versus disease. Many CNV detection softwares may misread the boundary of a CNV region, which could lead to a misclassification and result in false-positive or false-negative associations."
ParseCNV is designed with built-in corrections to adjust for these size variations and other red flags that confound results. Using polymerase chain reaction testing to validate the initial findings, the study team determined that the software had called 90 percent of the CNVs accurately—a better rate than conventional CNV association softwares, which typically produce validation rates that are notably lower.
The authors say the program's comprehensive design, statistical capabilities, and quality-control features lend it versatility, applicable not just to case-control studies, but also to family studies, and quantitative analyses of continuous traits, such as obesity or height.
Glessner says the Center for Applied Genomics team will continue to refine ParseCNV's features as CNV research progresses. Hakonarson adds that the ParseCNV algorithm will advance genomic diagnostics: "It is likely to play a future key role as a research tool in improving detection of CNV association in individual patients enrolled in disease studies—perhaps through an initial diagnostic screen, to be followed up with a CLIA-certified laboratory test."
INFORMATION:
An Institutional Development Award from The Children's Hospital of Philadelphia supported this research, along with the Cotswold Foundation and a donation from Adele and Daniel Kubert. The third co-author, also from the Children's Hospital genome center, was Jin Li.
"ParseCNV integrative copy number variation association software with quality tracking," Nucleic Acids Research, published online Jan. 4, 2013.
http://dx.doi.org/10.1093/nar/gks1346
About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 516-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.
END
This flu season you've probably seen a number of friends on social media talking about symptoms.
New research from Brigham Young University says such posts on Twitter could actually be helpful to health officials looking for a head start on outbreaks.
The study sampled 24 million tweets from 10 million unique users. They determined that accurate location information is available for about 15 percent of tweets (gathered from user profiles and tweets that contain GPS data). That's likely a critical mass for an early-warning system that could monitor terms like "fever," ...
NEW BRUNSWICK, N.J. – Coming out to one's family can be stressful, but gay black males face a unique set of personal, familial and social challenges.
"Parents and youths alike worry that gay men cannot meet the rigid expectations of exaggerated masculinity maintained by their families and communities," says Michael C. LaSala, director of the Master of Social Work program at Rutgers University School of Social Work. LaSala, an associate professor, recently completed an exploratory study of African American gay youth and their families from urban neighborhoods in New York ...
BUFFALO, N.Y. – New University at Buffalo research demonstrates how defects in an important neurological pathway in early development may be responsible for the onset of schizophrenia later in life.
The UB findings, published in Schizophrenia Research (paper at http://bit.ly/Wq1i41), test the hypothesis in a new mouse model of schizophrenia that demonstrates how gestational brain changes cause behavioral problems later in life – just like the human disease.
Partial funding for the research came from New York Stem Cell Science (NYSTEM).
The genomic pathway, called the ...
NEW YORK (January 22, 2013) -- A research study of more than 600 black patients with uncontrolled hypertension found that less than half were prescribed a diuretic drug with proven benefit that costs just pennies a day, report researchers at Weill Cornell Medical College and the Visiting Nurse Service of New York's (VNSNY) Center for Home Care Policy and Research. The researchers say these new findings should be taken as a serious wake-up call for physicians who treat black patients with hypertension.
Their study, reported in the American Journal of Hypertension, found ...
ALEXANDRIA, Va. – New research into the treatment and prognosis of gastrointestinal cancers was released today in advance of the tenth annual Gastrointestinal Cancers Symposium being held January 24-26, 2013, at The Moscone West Building in San Francisco, CA.
Five important studies were highlighted today in a live presscast:
Postoperative Treatment with S-1 Chemotherapy Reduces Relapses and Extends Survival in Patients with Pancreatic Cancer: Early results from a Phase III clinical trial conducted in Japan show patients who received the chemotherapy drug S-1 after ...
HOUSTON — Marked for death with molecular tags that act like a homing signal for a cell's protein-destroying machinery, a pivotal enzyme is rescued by another molecule that sweeps the telltale targets off in the nick of time.
The enzyme, called TRAF3, lives on to control a molecular network that's implicated in a variety of immune system-related diseases if left to its own devices.
The University of Texas MD Anderson scientists identified TRAF3's savior and demonstrated how it works in a paper published online Sunday in Nature.
By discovering the role of OTUD7B as ...
New York University College of Nursing (NYUCN) researchers Michele G. Shedlin, PhD, and Joyce K. Anastasi, PhD, DrNP, FAAN, LAc, published a paper, "Use of Complementary and Alternative Medicines and Supplements by Mexican-Origin Patients in a U.S.–Mexico Border HIV Clinic," in the on-line version of the Journal of the Association of Nurses in AIDS Care.
Complementary and alternative medicines (CAM) and therapies are often used to improve or maintain overall health and to relieve the side effects of conventional treatments or symptoms associated with chronic illnesses ...
SCOTTSDALE, Ariz. — Jan. 22, 2013 — A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment.
The MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study was led by physicians from Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).
Their findings show that Abraxane ...
A few years ago, manufacturers of water bottles, food containers, and baby products had a big problem. A key ingredient of the plastics they used to make their merchandise, an organic compound called bisphenol A, had been linked by scientists to diabetes, asthma and cancer and altered prostate and neurological development. The FDA and state legislatures were considering action to restrict BPA's use, and the public was pressuring retailers to remove BPA-containing items from their shelves.
The industry responded by creating "BPA-free" products, which were made from plastic ...
Technological advancements in medicine have allowed patients suffering from musculoskeletal conditions such as hip and knee pain to regain mobility and live relatively pain-free. But some "high risk" surgical devices that have been approved by the U.S. Food and Drug Administration (FDA) are not required to go through clinical trials, where a product is tested to determine its safety and effectiveness.
"This could be potentially very dangerous. Many Americans – patients and even physicians - are not aware of how many devices in this country are on the market without having ...
